Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 253


Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada.

Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ.

Can J Gastroenterol Hepatol. 2015 Jun 15. pii: 16942. [Epub ahead of print] No abstract available.


Comorbidities have a limited impact on post-transplant survival in carefully selected cirrhotic patients: a population-based cohort study.

Cardoso FS, Bagshaw SM, Abraldes JG, Kneteman NM, Meeberg G, Fidalgo P, Karvellas CJ.

Ann Hepatol. 2015 2015;14(4):505-514.


Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score >=40: A retrospective cohort study.

Cardoso FS, Karvellas CJ, Kneteman NM, Meeberg G, Fidalgo P, Bagshaw SM.

Can J Gastroenterol Hepatol. 2015 May;29(4):185-91.


Human islet function following 20 years of cryogenic biobanking.

Manning Fox JE, Lyon J, Dai XQ, Wright RC, Hayward J, van de Bunt M, Kin T, Shapiro AM, McCarthy MI, Gloyn AL, Ungrin MD, Lakey JR, Kneteman NM, Warnock GL, Korbutt GS, Rajotte RV, MacDonald PE.

Diabetologia. 2015 Jul;58(7):1503-12. doi: 10.1007/s00125-015-3598-4. Epub 2015 May 1.


STAT1 is phosphorylated and down-regulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large cell lymphoma.

Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, Kneteman NM, Lai R.

Blood. 2015 Apr 28. pii: blood-2014-10-603738. [Epub ahead of print]


Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter.

Jung K, Gupta N, Wang P, Lewis JT, Gopal K, Wu F, Ye X, Alshareef A, Abdulkarim BS, Douglas DN, Kneteman NM, Lai R.

Oncotarget. 2015 Apr 30;6(12):10366-73.


Generation of improved mouse models for the study of hepatitis C virus.

Douglas DN, Kneteman NM.

Eur J Pharmacol. 2015 Jul 15;759:313-325. doi: 10.1016/j.ejphar.2015.03.022. Epub 2015 Mar 23. Review.


Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.

Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM.

Hepatology. 2015 Jul;62(1):158-65. doi: 10.1002/hep.27787. Epub 2015 Apr 22.


Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes.

Roggenbeck BA, Carew MW, Charrois GJ, Douglas DN, Kneteman NM, Lu X, Le XC, Leslie EM.

Toxicol Sci. 2015 Jun;145(2):307-20. doi: 10.1093/toxsci/kfv051. Epub 2015 Mar 9.


Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.

Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS.

Eur J Surg Oncol. 2015 Jan;41(1):120-7. doi: 10.1016/j.ejso.2014.09.007. Epub 2014 Oct 7. Review.


Impact of adverse pancreatic injury at surgical procurement upon islet isolation outcome.

Andres A, Kin T, O'Gorman D, Bigam D, Kneteman N, Senior P, Shapiro AJ.

Transpl Int. 2014 Nov;27(11):1135-42. doi: 10.1111/tri.12392. Epub 2014 Aug 24.


Respiratory rate at intensive care unit discharge after liver transplant is an independent risk factor for intensive care unit readmission within the same hospital stay: a nested case-control study.

Cardoso FS, Karvellas CJ, Kneteman NM, Meeberg G, Fidalgo P, Bagshaw SM.

J Crit Care. 2014 Oct;29(5):791-6. doi: 10.1016/j.jcrc.2014.03.038. Epub 2014 Apr 24.


Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria.

Kashkoush S, El Moghazy W, Kawahara T, Gala-Lopez B, Toso C, Kneteman NM.

Clin Transplant. 2014 Jun;28(6):728-36. doi: 10.1111/ctr.12373. Epub 2014 May 10.


Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation.

Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, Beaumont C, Tandon P, Esfandiari N, Sawyer MB, Kneteman N.

Liver Transpl. 2014 Jun;20(6):640-8. doi: 10.1002/lt.23863. Epub 2014 Mar 26.


De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.

Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E, Roberts J, Kneteman N, Teperman L, Fung JJ, Millis JM.

Am J Transplant. 2014 Feb;14(2):356-66. doi: 10.1111/ajt.12543. Epub 2014 Jan 23.


Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies.

Foster JR, Lund G, Sapelnikova S, Tyrrell DL, Kneteman NM.

Xenobiotica. 2014 Jan;44(2):109-22. doi: 10.3109/00498254.2013.867553. Epub 2013 Dec 10. Review.


Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study.

Morard I, Gasche Y, Kneteman M, Toso C, Mentha A, Meeberg G, Mentha G, Kneteman N, Giostra E.

Neurocrit Care. 2014 Apr;20(2):287-95. doi: 10.1007/s12028-013-9928-9.


The Second Canadian Symposium on hepatitis C virus: a call to action.

Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, Roberts E, Choucha N, Myers RP, Sagan SM, Wilson JA, Bialystok F, Tyrrell DL, Houghton M, Krajden M; National CIHR Research Training Program in Hepatitis C.

Can J Gastroenterol. 2013 Nov;27(11):627-32.


Neurocognitive outcomes at kindergarten entry after liver transplantation at <3 yr of age.

Robertson CM, Dinu IA, Joffe AR, Alton GY, Yap JY, Asthana S, Acton BV, Sauve RS, Martin SR, Kneteman NM, Gilmour SM; Western Canadian Therapies Follow-up Group.

Pediatr Transplant. 2013 Nov;17(7):621-30. doi: 10.1111/petr.12134. Epub 2013 Aug 21. Erratum in: Pediatr Transplant. 2014 Feb;18(1):E40.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk